Proprietary pipeline of next generation immunology and immuno-oncology drugs.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
June 02, 2016

Key milestones achieved in collaboration with Intarcia

Intarcia Therapeutics, Inc., and Numab AG, today announced the…

Intarcia Therapeutics, Inc., and Numab AG, today announced the achievement of several key milestones in the development of a multi-specific antibody targeting inflammatory / autoimmune diseases. This is an important step towards realizing the potential of combining Numab’s antibody- based therapeutics with Intarcia’s unique delivery and formulation technologies. Read more in the PDF below.
June 09, 2015

Numab and Tillotts conclude license agreement for TNF blockers

Tillotts Pharma AG (“Tillotts”) and Numab AG announced today…

Tillotts Pharma AG (“Tillotts”) and Numab AG announced today that they have entered into an exclusive global licensing agreement to develop and commercialize new antibody-based therapies that act against tumor necrosis factor alpha (TNF-α) for people with inflammatory bowel disease (IBD). The partnership demonstrates Tillotts’ commitment to developing new treatments to improve care for patients with IBD and, upon successful development, will add to a strong track record in the registration and marketing of IBD treatments globally. Read more in the PDF below.
March 19, 2015

Numab and Intarcia sign strategic collaboration

Intarcia Therapeutics, Inc. and Numab AG today announced a…

Intarcia Therapeutics, Inc. and Numab AG today announced a strategic collaboration focused on the development of once- or twice-yearly mono-specific and multi-specific antibodies addressing diabetes, obesity and autoimmune indications. Read more in the PDF below.
More News